Nektar Therapeutics 8-K filings

Nektar Therapeutics shareholders approved the election of a director, an increase in incentive plan shares, and the ratification of auditors at the 2026 Annual Meeting.

Nektar Therapeutics has entered into an equity distribution agreement to sell up to $150 million of its common stock through an at-the-market offering program.

Nektar Therapeutics announced the pricing of an upsized public offering of $325 million of its common stock, with net proceeds expected to be approximately $350.9 million.

Nektar Therapeutics announced a cash and marketable securities balance of approximately $741.7 million as of April 1, 2026.

Nektar Therapeutics announced 52-week topline results from the REZOLVE-AA study extension, showing continued hair regrowth in patients with severe-to-very-severe alopecia areata treated with rezpegaldesleukin.

Nektar Therapeutics reported its fourth quarter and full year 2025 financial results, highlighting a strengthened financial position and progress in its clinical pipeline, despite a significant increase in net loss.

Nektar Therapeutics announced it held approximately $229.1 million in cash and marketable securities as of January 31, 2026.

Nektar Therapeutics announced positive 36-week maintenance data for rezpegaldesleukin in moderate-to-severe atopic dermatitis, demonstrating sustained and deepening responses with a favorable safety profile.

Nektar Therapeutics has entered a quiet period in anticipation of analyzing and publicly announcing data from the 36-week maintenance period of its Phase 2b REZOLVE-AD study for rezpegaldesleukin in atopic dermatitis.

Nektar Therapeutics announced positive topline results from its Phase 2b REZOLVE-AA trial for alopecia areata, establishing proof-of-concept and supporting advancement to Phase 3.

Nektar Therapeutics announced Mark A. Wilson will step down as Chief Legal Officer, with Elizabeth Zhang assuming his responsibilities.

Nektar Therapeutics announced new Phase 2b data for rezpegaldesleukin, demonstrating statistically significant and clinically meaningful improvements in asthma control for atopic dermatitis patients.

Nektar Therapeutics reported third quarter 2025 financial results, highlighting a decrease in revenue and net loss, alongside significant clinical progress for rezpegaldesleukin.

Nektar Therapeutics announced positive new data from its REZOLVE-AD Phase 2b study for rezpegaldesleukin in moderate-to-severe atopic dermatitis, meeting primary and key secondary endpoints with a favorable safety profile.

Nektar Therapeutics announced its second quarter 2025 financial results, reporting decreased revenue and increased net loss, while extending its cash runway into Q1 2027 following a recent public offering.

Nektar Therapeutics announced the pricing of an underwritten public offering of common stock, expected to generate approximately $93.7 million in net proceeds to fund general corporate purposes, including research and development.

Nektar Therapeutics announced it has successfully regained compliance with Nasdaq's minimum bid price rule, ensuring its continued listing on The Nasdaq Capital Market.

Nektar Therapeutics today announced statistically significant positive topline results from its Phase 2b REZOLVE-AD clinical trial for rezpegaldesleukin in moderate-to-severe atopic dermatitis, validating its novel T-regulatory cell mechanism.

Nektar Therapeutics has announced a 1-for-15 reverse stock split to take effect on June 8, 2025, alongside an increase in authorized common shares from 300 million to 390 million, both approved by stockholders.

Nektar Therapeutics has announced a one-for-fifteen reverse stock split, effective June 8, 2025, aiming to increase its common stock's per-share trading price.

Nektar Therapeutics announced that its stockholders approved the election of two directors, an increase in authorized shares for its incentive plan, ratification of its auditor, executive compensation, an increase in total authorized common stock, and a potential reverse stock split at its Annual Meeting.

Nektar Therapeutics announced its first quarter 2025 financial results, highlighting progress in clinical trials and a decrease in year-over-year revenue due to the sale of its manufacturing facility.

Nektar Therapeutics received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, potentially leading to delisting.

Nektar Therapeutics has entered into an agreement to potentially sell up to $75 million in common stock through an at-the-market offering.

Nektar Therapeutics announces improved financial results for Q4 and full year 2024, driven by increased revenue and reduced operating expenses, alongside promising progress in its immunology pipeline.

Nektar Therapeutics partners with TrialNet to conduct a Phase 2 clinical trial evaluating rezpegaldesleukin in patients with new onset stage 3 type 1 diabetes mellitus.

Mary Tagliaferri MD resigned from her position as Senior Vice President and Chief Medical Officer of Nektar Therapeutics, effective immediately, and Brian Kotzin, MD, has assumed the responsibilities of interim Chief Medical Officer.

Nektar Therapeutics has completed the sale of its Huntsville, Alabama manufacturing facility and related assets to an affiliate of Ampersand Capital Partners.

Nektar Therapeutics announced its third quarter 2024 financial results, highlighting progress in its clinical pipeline and a strategic sale of its commercial PEGylation manufacturing business.

Nektar Therapeutics has agreed to sell its Alabama manufacturing facility and reagent supply business to Ampersand Capital Partners for $90 million, including cash and equity.